An initial article summarizing the results of CREDO 2, by now the largest phase III clinical trial of Artlegia (olokizumab) has been published in New England Journal of Medicine. Artlegia is an original proprietary medicine developed by the R-Pharm group.
The New England Journal of Medicine, published by the Massachusetts Medical Society, is the oldest continuously published medical journal and is among the top three most read journals in this area, ranking first in its impact index.
The CREDO 2 phase III trial included 1648 patients from 18 countries and had and up-to-date design, featuring a comparator agent and a short placebo period (of 24 weeks). Trial results demonstrated efficacy and safety of the studied treatment.
“The New England Journal of Medicine publication on olokizumab illustrates the successful global clinical research program and supports the promising R-Pharms’ strategy in autoimmune disease focused on patients’ needs“, – commented Mikhail Samsonov, the company Chief Medical Officer.
Artlegia (olokizumab) is a humanized monoclonal antibody specific to proinflammatory cytokine interleukine-6 (IL-6). This product interacts not with IL-6 itself, but with its receptor, selectively blocking the end-stage assembly of the signaling complex.
Olokizumab is the first interleukine-6 (IL-6) inhibitor approved for the treatment of patients with moderate to severe rheumatoid arthritis in combination with methotrexate, after failure of methotrexate or TNF inhibitors (a difficult to treat population after failure of at least one biologic treatment).